The impact of chronic conditions on the economic burden of cancer survivorship: a systematic review

Abstract

Introduction This systematic review examines the excess cost of chronic conditions on the economic burden of cancer survivorship among adults in the US. Areas covered Twelve published studies were identified. Although studies varied substantially in populations, comorbidities examined, methods, and types of cost reported, costs for cancer survivors with comorbidities generally increased with greater numbers of comorbidities or an increase in comorbidity index score. Survivors with comorbidities incurred significantly more in total medical costs, out-of-pocket costs, and costs by service type compared to cancer survivors without additional comorbidities. Expert commentary Cancer survivors with comorbidities bear significant excess out-of-pocket costs and their care is also more expensive to the healthcare system. On-going evaluation of different payment models, care coordination, and disease management programs for cancer survivors with comorbidities will be important in monitoring impact on healthcare costs.

Association between anxiety, depression, and comorbid chronic diseases among cancer survivors

“…CCD are highly prevalent in cancer patients, with reports indicating that 68.7% of CSs had comorbidity . CCD were associated with increased health‐care cost, poorer quality of life, and poorer cancer survival …”

Examining the role of social support and spirituality on the general health perceptions of Hispanic cancer survivors

“…It has been found that cancer survivors are more likely to delay or forgo medical care because of cost compared with adults without a history of cancer . Furthermore, cancer survivors with comorbid conditions, at any point in the survivorship continuum, are more likely to experience higher financial burden as they are more vulnerable to out‐of‐pocket costs . In the United States, Hispanics are more likely to live in poverty and are less likely to be insured, compared with non‐Hispanic whites; this creates several stressors and financial barriers that impact having a usual source of care .…”

Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era

“…There are approximately 15.5 million cancer survivors in the US, and there may be substantial costs to clinically manage the toxicities that could result from treatment of their disease (84). Cardiac complications that can develop after RT to the chest area (in breast cancer or lung cancer), for example, can be substantial.…”